Does having HIV affect response to hepatitis C treatment?
WHO issues new hepatitis C guidelines, EASL guidelines update forthcoming in September
Hepatitis C therapy improves quality of life for people who inject drugs, but reinfection risk remains
People treated for hepatitis C have unexpectedly high rate of liver cancer recurrence
Portugal's roll-out of HCV therapy with DAAs achieves impressive results
DAAs achieve excellent outcomes in real-world settings
High incidence of HCV reinfection among HIV-positive MSM in Western Europe
Sofosbuvir/velpatasvir cures HCV in 95% of people with HCV and HIV co-infection
Six weeks of sofosbuvir/ledipasvir is enough to cure acute hepatitis C in HIV-negative people
Tenofovir alafenamide works well against hepatitis B with less effect on bones and kidneys
Low-cost generic hepatitis C drugs match branded products in viral response
Shifting hepatitis C treatment to primary care providers could expand availability
Sofosbuvir/velpatasvir + GS-9857 works well for treatment-experienced hepatitis C patients
Hepatitis C treatment may not be enough to stop the progress of advanced liver disease, or reduce liver transplant need
